Stephan Mielke

Professor of Hematology and Cell Therapy

Karolinska Institutet

Sweden

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Immunology

20%

Internal Medicine

20%

Stem Cell Transplantation

30%

Hematology

30%

Graft-versus-host Disease

20%

Transplantation

20%

Targeted Therapy

10%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant.

Article Link

Year:

2024

Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT.

Article Link

Year:

2024

Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Article Link

Year:

2024

Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.

Article Link

Year:

2024

Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.

Article Link

Year:

2024

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Article Link

Year:

2024

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.

Article Link

Year:

2024

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

Article Link

Year:

2024

Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party.

Article Link

Year:

2023

Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Article Link

Year:

2023

Collaborators6

Rafael de la Camara

- Head of Haematology

Hospital Universitario Virgen del Rocío

SPAIN

Matthew Collin

Professor of Haematology

Newcastle University

UNITED KINGDOM

Peter Bergman

Karolinska University Hospital

SWEDEN

KRZYSZTOF KALWAK

MD, PhD, Prof.

Wroclaw Medical University

POLAND

Margaret Sällberg Chen

Karolinska Institutet

SWEDEN

Grzegorz Helbig

POLAND

How do I reach out?

Meet Kite AI